Arca
Skip to content
Tools
Tools

CD3E: T-cell surface glycoprotein CD3 epsilon chain

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response.

  • Drugs that act on it: 7
  • Approved: 1
  • In phases 1 to 3: 6
  • Sponsors: 6

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD3E, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Other

Approved1

  • Teplizumab

Phase 33

  • HOKT3
  • Otelixizumab
  • Visilizumab

Phase 22

  • Ertumaxomab
  • Resimmune

Phase 11

  • MEDI-565

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Facet Biotech114%
  • MedImmune LLC114%
  • Neovii Biotech114%
  • Virogen Biotechnology Inc.114%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Antibody457%
  • Other343%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
TeplizumabApprovedSanofiAntibodyOtherT-cell surface glycoprotein CD3 epsilon chain other10—
HOKT3Phase 3—OtherInhibitorT-cell surface glycoprotein CD3 epsilon chain inhibitor0—
OtelixizumabPhase 3GSKAntibodyBinding agentT-cell surface glycoprotein CD3 epsilon chain binding agent0—
VisilizumabPhase 3Facet BiotechAntibodyInhibitorT-cell surface glycoprotein CD3 epsilon chain inhibitor0—
ErtumaxomabPhase 2Neovii BiotechAntibodyCross-linking agentT-cell surface glycoprotein CD3 epsilon chain cross-linking agent0—
ResimmunePhase 2Virogen Biotechnology Inc.OtherBinding agentT-cell surface glycoprotein CD3 epsilon chain binding agent0—
MEDI-565Phase 1MedImmune LLCOtherCross-linking agentT-cell surface glycoprotein CD3 epsilon chain cross-linking agent0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Immunodeficiency 18
0.74
Neoplasm
0.60
Plasma cell myeloma
0.60
Type 1 diabetes mellitus
0.56
Small cell lung carcinoma
0.56
Cancer
0.50
T-B- severe combined immunodeficiency
0.46

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
CD3E

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1975, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P07766, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.